Antifungals in the treatment of allergic bronchopulmonary aspergillosis

Eddie E. Leon, Timothy Craig

Research output: Contribution to journalReview article

37 Citations (Scopus)

Abstract

Objective: The primary objective of this article was to review the therapy of allergic bronchopulmonary aspergillosis (ABPA), especially to determine if antifungal therapy has a role in treatment of the disease. Data Sources: We researched MEDLINE for all published studies on the use of antifungal therapy in ABPA. We also surveyed the literature for articles pertinent in the diagnosis and treatment of ABPA. We included all publications from MEDLINE written in English and non-English publications with English abstracts. Study selection: All studies were reviewed. Case reports and small studies are presented. No well placebo-controlled, blinded, parallel studies were located for review. Results: Oral corticosteroids are still the therapy of choice for ABPA. Itraconazole may have a role in therapy, but controlled studies are needed. At this time itraconazole should be limited to cases where oral corticosteroids are contraindicated or refused by the patient. In patients requiring large doses of oral steroids, itraconazole may allow a reduction in dose, but should not replace the need to treat with oral corticosteroids. Conclusions: Antifungal agents, in particular itraconazole may have a role in the treatment of ABPA, but more data are necessary to confirm the efficacy of itraconazole in ABPA.

Original languageEnglish (US)
Pages (from-to)511-517
Number of pages7
JournalAnnals of Allergy, Asthma and Immunology
Volume82
Issue number6
DOIs
StatePublished - Jan 1 1999

Fingerprint

Allergic Bronchopulmonary Aspergillosis
Itraconazole
Adrenal Cortex Hormones
Therapeutics
MEDLINE
Publications
Antifungal Agents
Information Storage and Retrieval
Steroids
Placebos

All Science Journal Classification (ASJC) codes

  • Immunology and Allergy
  • Immunology
  • Pulmonary and Respiratory Medicine

Cite this

@article{9656ab4b8fa2469ead73a05399530077,
title = "Antifungals in the treatment of allergic bronchopulmonary aspergillosis",
abstract = "Objective: The primary objective of this article was to review the therapy of allergic bronchopulmonary aspergillosis (ABPA), especially to determine if antifungal therapy has a role in treatment of the disease. Data Sources: We researched MEDLINE for all published studies on the use of antifungal therapy in ABPA. We also surveyed the literature for articles pertinent in the diagnosis and treatment of ABPA. We included all publications from MEDLINE written in English and non-English publications with English abstracts. Study selection: All studies were reviewed. Case reports and small studies are presented. No well placebo-controlled, blinded, parallel studies were located for review. Results: Oral corticosteroids are still the therapy of choice for ABPA. Itraconazole may have a role in therapy, but controlled studies are needed. At this time itraconazole should be limited to cases where oral corticosteroids are contraindicated or refused by the patient. In patients requiring large doses of oral steroids, itraconazole may allow a reduction in dose, but should not replace the need to treat with oral corticosteroids. Conclusions: Antifungal agents, in particular itraconazole may have a role in the treatment of ABPA, but more data are necessary to confirm the efficacy of itraconazole in ABPA.",
author = "Leon, {Eddie E.} and Timothy Craig",
year = "1999",
month = "1",
day = "1",
doi = "10.1016/S1081-1206(10)63157-2",
language = "English (US)",
volume = "82",
pages = "511--517",
journal = "Annals of Allergy, Asthma and Immunology",
issn = "1081-1206",
publisher = "American College of Allergy, Asthma and Immunology",
number = "6",

}

Antifungals in the treatment of allergic bronchopulmonary aspergillosis. / Leon, Eddie E.; Craig, Timothy.

In: Annals of Allergy, Asthma and Immunology, Vol. 82, No. 6, 01.01.1999, p. 511-517.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Antifungals in the treatment of allergic bronchopulmonary aspergillosis

AU - Leon, Eddie E.

AU - Craig, Timothy

PY - 1999/1/1

Y1 - 1999/1/1

N2 - Objective: The primary objective of this article was to review the therapy of allergic bronchopulmonary aspergillosis (ABPA), especially to determine if antifungal therapy has a role in treatment of the disease. Data Sources: We researched MEDLINE for all published studies on the use of antifungal therapy in ABPA. We also surveyed the literature for articles pertinent in the diagnosis and treatment of ABPA. We included all publications from MEDLINE written in English and non-English publications with English abstracts. Study selection: All studies were reviewed. Case reports and small studies are presented. No well placebo-controlled, blinded, parallel studies were located for review. Results: Oral corticosteroids are still the therapy of choice for ABPA. Itraconazole may have a role in therapy, but controlled studies are needed. At this time itraconazole should be limited to cases where oral corticosteroids are contraindicated or refused by the patient. In patients requiring large doses of oral steroids, itraconazole may allow a reduction in dose, but should not replace the need to treat with oral corticosteroids. Conclusions: Antifungal agents, in particular itraconazole may have a role in the treatment of ABPA, but more data are necessary to confirm the efficacy of itraconazole in ABPA.

AB - Objective: The primary objective of this article was to review the therapy of allergic bronchopulmonary aspergillosis (ABPA), especially to determine if antifungal therapy has a role in treatment of the disease. Data Sources: We researched MEDLINE for all published studies on the use of antifungal therapy in ABPA. We also surveyed the literature for articles pertinent in the diagnosis and treatment of ABPA. We included all publications from MEDLINE written in English and non-English publications with English abstracts. Study selection: All studies were reviewed. Case reports and small studies are presented. No well placebo-controlled, blinded, parallel studies were located for review. Results: Oral corticosteroids are still the therapy of choice for ABPA. Itraconazole may have a role in therapy, but controlled studies are needed. At this time itraconazole should be limited to cases where oral corticosteroids are contraindicated or refused by the patient. In patients requiring large doses of oral steroids, itraconazole may allow a reduction in dose, but should not replace the need to treat with oral corticosteroids. Conclusions: Antifungal agents, in particular itraconazole may have a role in the treatment of ABPA, but more data are necessary to confirm the efficacy of itraconazole in ABPA.

UR - http://www.scopus.com/inward/record.url?scp=0033062690&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033062690&partnerID=8YFLogxK

U2 - 10.1016/S1081-1206(10)63157-2

DO - 10.1016/S1081-1206(10)63157-2

M3 - Review article

C2 - 10400477

AN - SCOPUS:0033062690

VL - 82

SP - 511

EP - 517

JO - Annals of Allergy, Asthma and Immunology

JF - Annals of Allergy, Asthma and Immunology

SN - 1081-1206

IS - 6

ER -